Fundraising FoxAllinaire Therapeutics
2 known investors
Find your way into Allinaire Therapeutics
Sign up to see every warm intro you have to Allinaire Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Allinaire Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Allinaire Therapeutics is developing humanized anti-EMAP II monoclonal antibodies as a potential disease-modifying treatment for pulmonary arterial hypertension (PAH) and other cardiopulmonary diseases such as COPD and viral-induced acute lung injury. The company was founded on technology licensed from Indiana University.
Founders & leadership
MC
Matthias ClaussScientific Founder
IP
Irina PetracheScientific Founder
Investors · 2
Reported raises · per SEC filings
Form D private placements▶$700KraisedApr 2026 · 2 investors · OtherRule 506(b)
▶$700KraisedApr 2026 · 2 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Douglas W.P. HayExecutive Officer, Director
- Satish JindalDirector
- Arthur BertelsonDirector
- Samantha GintherDirector
- Offering amount
- $700K
- Amount sold
- $700K
- First sale
- Jan 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.6MraisedDec 2018 · 8 investors · PharmaceuticalsRule 506(b)
▶$1.6MraisedDec 2018 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Ted TorphyDirector
- Baiju ShahExecutive Officer, Director
- Brian StemmeDirector
- Offering amount
- $5M
- Amount sold
- $1.6M
- First sale
- Dec 2016
- Incorporated
- Limited Liability Company, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Allinaire Therapeutics do?
- Allinaire Therapeutics is developing humanized anti-EMAP II monoclonal antibodies as a potential disease-modifying treatment for pulmonary arterial hypertension (PAH) and other cardiopulmonary diseases such as COPD and viral-induced acute lung injury. The company was founded on technology licensed from Indiana University.
- Who are Allinaire Therapeutics's investors?
- Allinaire Therapeutics's investors include Advent Life Sciences, IU Ventures.